Predictive value of echocardiography in assessment of all-cause death in cardio-oncologic patients: a single-center prospective registry

Clicks: 1
ID: 323289
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #187 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Anticancer treatment-induced cardiovascular cardiotoxicity is related to cardiovascular and all-cause mortality in patients with cancer. We have evaluated the association between echocardiographic findings and all-cause mortality, especially cardiovascular mortality in our cardio-oncologic patient cohort. Methods Totally 674 patients were included into our Cardio-Oncologic Registry, who visited our cardio-oncologic outpatient care due to suspicious cardiotoxicity. Clinical data (age, sex, date of visit, survival status, date of death, atrial fibrillation) baseline and follow-up echocardiographic data and type of cancer, routine laboratory parameter (among others troponin T, NT-proBNP, creatine), and the main oncologic diagnosis with ICD codes (retrieved from the hospital documentation) were recorded at the baseline and the at the final visiting date. Results The mean age of the 674 patients (346 male /51.3%/ and 328 female /48.7%) was 71±13.1 years. Permanent atrial fibrillation was recorded in 156 patients (21.3%). High proportion of patients (n=450, 66.8%) had already metastases at the first visit. Baseline echocardiography was performed in 516 (76.6%) patients, while 316 patients (46.9%) underwent follow-up echocardiography. Left ventricular function worsened in 81/316 patients (25.6%) during the mean follow-up time of 24±12 months. Both the troponin T and NT-proBNP values were already elevated at the first clinical visit, while the mild reduced kidney function did not change. Totally 204 patients (30.3%) died during the 35.2 ±18.5 months visit duration. According to the Austrian Mortality Statistics, 20 of 204 patients (9.8%) died due to cardiovascular complications. Table 1 lists the clinical, laboratory and echocardiographic data of the survival and non-survival patients. Conclusions Our prospective registry involving unselected cancer patients with high incidence of metastases revealed high mortality in patients with suspected cardiotoxicity, with a relatively low incidence of 9.8% cardiovascular death.Table 1
Reference Key
openalex_W7172263897 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors V Kokabi, A Spannbauer, H Erdogan, A Domanig, C Kronberger, T Fuereder, R Bartsch, C Hengstenberg, M Preusser, M Raderer, B Kiesewetter, M Gyoengyoesi, J Bergler-Klein
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.043
URL
https://doi.org/10.1093/eurheartjsupp/suag097.043
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.